Inherited thrombophilia and pregnancy

Current Opinion in Obstetrics and Gynecology

Volumn 10, Issue 2, 1998, Pages 135-144

  Girling, Joanna ^a   De Swiet, Michael ^b  

^a WEST MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^b QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; FOLIC ACID; HOMOCYSTEINE; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOMODULIN;

ACTIVATED PROTEIN C RESISTANCE; ANTITHROMBIN III DEFICIENCY; FAMILIAL DISEASE; FEMALE; FETUS WASTAGE; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK ASSESSMENT; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; THROMBOEMBOLISM; THROMBOPHILIA;

BIOLOGICAL MARKERS; FEMALE; HOMOCYSTEINE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PROTEIN C; RISK; RISK FACTORS; THROMBOPHILIA;

EID: 0031944566     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199804000-00010     Document Type: Review

References (67)

1. Report on Confidential Enquiry into Maternal Deaths in the United Kingdom 1991-93. London: HMSO; 1996.
2. Beyth RJ, Cohen AM, Landefield C. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995; 155:1031-1037.
3. de Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996; 87:3531-3544.
4. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: a review of 404 cases. Thromb Haemost 1987; 58:1094.
5. Bauters A, Zawadzki C, Bura A, Watel A, Subtil D, Aiach M, et al. Homozygous variant of antithrombin with lack of affinity for heparin: management of severe thrombotic complications associated with fetal demise. Blood Coag Fibrinolysis 1996; 7:705-710.
6. Conard J, Horellou MH, van Dreden P, Le Compte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S. Thromb Haemost 1990; 63:319-320.
7. Tait RC, Walker ID, Perry DJ, Islam SIAM, Daly ME, McCall F, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87:106-112.
8. Tait RC, Walker JD, Reitsma PH, Islam SIAM, McCall F, Poort SR, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73:87-93.
9. Faught W, Garner PJ, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol 1995; 72:147-150.
10. Lefkowitz JB, Clarke SH, Barbour LA. Comparison of protein S functional and antigenic assays in normal pregnancy. Am J Obstet Gynecol 1996; 175:657-660.
11. Aillaud MF, Pouymayou K, Brunet D, Parrot G, Alessi MC, Amiral J, Juhan-Vague I. New direct assay of free protein S antigen applied to diagnosis of protein S deficiency. Thromb Haemost 1996; 75:283-285.
12. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-1008.
13. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277:1305-1307.
14. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
15. Dahlback B. Are we ready for factor V Leiden screening? Lancet 1996; 347:1346-1347.
16. Walker MC, Garner PR, Keely EJ, Rock GA, Reis MD. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177:162-169.
17. Cumming AM, Tait RC, Fildes S, Yong A, Keeney A, Hay CRM. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90:725-727.
18. Peek MJ, Nelson-Piercy C, Manning RA, de Swiet M, Letsky EA. Activated protein C resistance in normal pregnancy. Br J Obstet Gynaecol 1997; 10:1084-1086.
19. Mathonnet F, de Mazancourt P, Bastenaire B, Morot M, Benattar N, Beufe S, et al. Activated protein C sensitivity ratio in pregnant women at delivery. Br J Haematol 1996; 92:244-246.
20. Schlit A-F, Col-De Beys C, Moriau M, Lavenne-Pardogne E. Acquired activated protein C resistance in pregnancy. Thromb Res 1996; 84:203-206.
21. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14:127-141.
22. de Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodegliero F, Castman G, et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C. protein S. Thromb Haemost 1994; 71:799-800.
23. Vicente V, Rodriguez C, Soto I, Fernandez M, Moraleda JM. Risk of thrombosis during pregnancy and post-partum in hereditary thrombophilia. Am J Haematol 1994; 46:151-152.
24. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III protein C or protein S deficiency. Arterioscler Thromb Vasc Biol 1996; 16:742-748.
25. Friederich PW, Sanson B-J, Simioni P, Zanardi S, Huisman MV, Kindt I, et •• al. Frequency of pregnancy-related venous thromboembolism in anticoagulant-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955-960. A survey of families with thrombophilia, suggesting lower rates of thrombosis in pregnancy than earlier studies, possibly because of a stricter definition of thrombotic events and less selection bias.
26. Nelson-Piercy C, Letsky EA, de Swiet M. Low molecular weight heparin for obstetric thromboprophylaxis: experience of sixty nine pregnancies in sixty one women at high risk. Am J Obstet Gynecol 1997; 176:1062-1068.
27. Hallak M, Senderowicz J, Cassel A, Shapira C, Aghai E, Auslender R, Abramovici H. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176:889-893.
28. Bokarewa MI, Bremme K, Blomback M. Arg 506 - Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92:473-478.
29. Hough RE, Makris M, Preston FE. Pregnancy in women with thrombophilia: incidence of thrombosis and pregnancy outcome [abstract]. Br J Haematol 1996; 93 (suppl. 2):136.
30. de Stefano V, Mastrangelo S, Paciaroni K, Ireland H, Lane DA, Scirpa P, et al. Thrombotic risk during pregnancy and puerperium in women with APC resistance. Effective subcutaneous heparin prophylaxis in a pregnant patient. Thromb Haemost 1995; 74:793-794.
31. Melichart M, Kyrle PA, Eichinger S, Rintelen C, Mannhalter C, Pabinger I. Thrombotic tendency in 75 symptomatic unrelated patients with APC resistance. Wien Klin Wochenschr 1996; 108:607-610.
32. Dahlman T. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265-1270.
33. Rizzoli R, Bonjour JP. Pregnancy-associated osteoporosis. Lancet 1996; 347:1274-1276.
34. Walker ID. Congenital thrombophilia. In Baillieres clinical obstetrics and • gynaecology, thromboembolic disease in obstetrics and gynaecology. Vol. 11. Greer IA (editor). London: Bailliere Tindall; 1997. pp. 431-445. A good and up-to-date summary of the role of inherited thrombophilia in obstetrics.
35. Vandenbroucke JP, van der Meer FJM, Heimerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraception users and pregnant women? BMJ 1996; 313:1127-1130.
36. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann intern Med 1997; 127:895-903.
37. van Boven HH, Reitsma PH, Rosendaal FR, Bayston BA, Chowdhury V, Bauer KA, et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75:417-421.
38. Zoller B, Berntsdotter A, de Frutos PG, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85:3518-3523.
39. Koeleman BPC, van Rumpt D, Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74:580-583.
40. Koeleman BPC, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994; 84:1031-1035.
41. Mannhalter HC, Melichart M, Knobi P, Lechner K, Pabinger I. Risk of thrombosis in relatives of symptomatic patients with factor V Leiden [abstract]. Br J Haematol 1996; 93 (suppl. 2):137.
42. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. •• Increased fetal loss in women with heritable thrombophilia. Lancet 1996 348:913-916. An interesting study of 571 women with inherited thrombophilia and 541 controls, showing that combined defects or antithrombin III deficiency are associated with an increased risk of fetal loss.
43. Sanson B-J, Friederich PW, Simioni P, Zanard S, Huisman MV, Girolami A, et al. The risk of abortion and stillbirth in antithrombin protein C and protein S deficient women. Thromb Haemost 1996; 75:387-388.
44. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996; 92:489-490.
45. Brenner B, Mandel MH, Lanir N, Younis J, Rothbart H, Ohel G, Blumenfeld Z. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97:551-554.
46. Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997; 177:402-405.
47. Dekker GA, de Vries JIP, Doelrtzsch PM, Huijgens PC, von Blomberg BME, Jakobs C, van Geijn HP. Underlying disorders associated with severe early onset preeclampsia. Am J Obstet Gynecol 1995; 173:1042-1048.
48. Lindoff C, lngemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997; 176:457-460.
49. Brenner B, Lanir N, Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol 1996; 92:999-1001.
50. Rotmensch S, Liberati M, Mittelmann M, Ben-Rafael Z. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol 1997; 177:170-173.
51. CLASP (Collaborative low-dose aspirin study in pregnancy) Collaborative Group. CLASP: a randomised trial of low dose aspirin for the prevention and treatment of 9364 pregnant women. Lancet 1994; 343:616-629.
52. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314:253-257.
53. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584-1589.
54. van den Berg M, Boers GHJ. Homocystinuria: what about mild hyperhomocystinaemia? Postgrad Med J 1996; 72:513-518.
55. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998; 351:36-37.
56. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, et • al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red cell folates: implications for folate intake recommendations. Lancet 1997; 349:1591-1593. This newly described mutation, resulting in mild hyperhomocysteinaemia, in pregnancy, is associated with a lower folate level even in the heterozygote state. This has implications for the management of folate deficiency and the prevention of neural tube defect, as well as potentially for the prevention of thromoembolism.
57. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, et al. Hyperhomocysteinaemia as a risk factor for deep vein thrombosis. N Engl J Med 1996; 334:759-762.
58. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis. Lancet 1995; 345:882-885.
59. van der Put NMJ, Eskes TKAB, Blom HJ. Is the common 667C-T mutation in methylene tetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. Q J Med 1997; 90:111-115.
60. Wilcken DEL. MTHFR 677C-T mutation, folate intake neural tube defect and risk of cardiovascular disease. Lancet 1997; 350:603-604.
61. Nelen WLDM, Steegers EAP, Eskes TKAB, Blom HJ. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet 1997; 350:861.
62. Nelen WLDM, van der Molen EF, Blom HJ, Heil SG, Steegers EAP, Eskes TKAB. Recurrent early pregnancy loss and genetic-related disturbances in folate and homocysteine metabolism. Br J Hosp Med 1997; 58:511-513.
63. de Vries JIP, Dekker GA, Huijgens PC, Jakobs C, Blomberg BME, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997; 104:1248-1254.
64. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic • variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703. The first study to descibe a new form of inherited thrombophilia, namely prothrombin gene mutation.
65. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a UK anticoagulant clinic population. Br J Haematol 1997; 98:353-355.
66. Dahlback B. The protein C anticoagulant system: inherited defects as a basis for venous thrombosis. Thromb Res 1995; 77:1-43.
67. Ohlin A-K, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995; 85:330-336.